SAN DIEGO, Oct. 9 /PRNewswire-FirstCall/ -- Sequenom, Inc. , a leading provider of fine mapping genotyping, methylation and gene expression analysis solutions, today announced the launch of its latest generation multiplex genotyping product, the iPLEX(TM) Gold assay. This assay enables a typical fine mapping genotyping study for about 3 1/2 cents per data point by providing routine multiplexing at 36 times per reaction and, depending upon the complexity of the specific assay, up to 40 times per reaction. This represents customer savings of approximately 25% per study compared to the original iPLEX assay and improves project efficiency.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)
“The iPLEX Gold assay is an example of our continuous work to provide customers with the highest value products. This new assay was developed to meet the growing need for high value fine mapping genotyping solutions to further support researchers as they complete whole genome studies,” said Michael Monko, Senior Vice-President of Sales & Marketing. “The iPLEX Gold assay provides the same accurate and high quality results as our original iPLEX assay at a substantially reduced cost per data point, and its increased multiplexing power delivers more information faster.”
Additional benefits and product details for the iPLEX Gold assay will be unveiled at a workshop conducted by Sequenom on October 10th at the annual meeting of The American Society of Human Genetics. The assay, which conveniently runs on Sequenom’s currently available MassARRAY(R) Compact system, will be commercially available by 2006 year end. The iPLEX Gold assay is also available as a service offering through Sequenom’s genetic analysis services business unit.
“We became a leader in fine mapping genotyping solutions, facilitated in part by last year’s introduction of our iPLEX multiplexing assay. We are building on that success with the launch of our next-generation iPLEX Gold assay,” said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. “The introduction of the iPLEX Gold assay marks an important milestone in our business transformation and our overall corporate goal to provide quality genetic analysis solutions.”
About Sequenom
Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, agricultural applications, molecular medicine, and non-invasive prenatal testing. The Company’s proprietary MassARRAY system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. The Company has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms.
Sequenom(R), MassARRAY(R), and iPLEX(TM) are trademarks of SEQUENOM, Inc.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the growing need for high value fine mapping genotyping solutions, the workshop to be conducted by the Company, and commercial availability of the iPLEX Gold assay by 2006 year end, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company’s technologies, market acceptance of and demand for the Company’s products, product development and commercialization, and other risks detailed from time to time in the Company’s SEC reports, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 and subsequent periodic reports. These forward-looking statements are based on current information that is likely to change and speak only as of the date hereof. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSequenom, Inc.
CONTACT: John Sharp, Principal Financial Officer of Sequenom, Inc.,+1-858-202-9032; or Investors, Zachary Bryant, zbryant@lhai.com, or JodyCain, jcain@lhai.com, both of Lippert/Heilshorn & Associates,+1-310-691-7100, for Sequenom, Inc.
